SEARCH
Search Details
Yamazaki Hiroyuki
| Hokkaido University Hospital Division of Child Maternal and Female medicine | Assistant Professor |
Researcher basic information
■ Degree■ URL
researchmap URLホームページURL■ Various IDs
Researcher number
- 70980407
Research Field
Research activity information
■ Papers- Feasibility study of photoimmunotherapy combination with ASP-1929 for vulvar, vaginal, and cervical cancer.
Ryutaro Yamamoto; Hiroshi Asano; Kanako C Hatanaka; Yoshiki Shinomiya; Hiroyuki Yamazaki; Hiroko Matsumiya; Michiko Nagamine; Yuko Sasajima; Yutaka Hatanaka; Hidemichi Watari
Journal of gynecologic oncology, 21 May 2026, [International Magazine]
English, Scientific journal, OBJECTIVE: The aim of this study was to evaluate the feasibility of photoimmunotherapy (PIT) using ASP-1929, an anti-epidermal growth factor receptor (EGFR) antibody-dye conjugate, for vulvar, vaginal, and cervical cancers by validating EGFR expression and establishing immunohistochemistry (IHC)-based eligibility criteria for a phase II trial, HICARi study. METHODS: Cetuximab-binding activity was analyzed in gynecologic cancer cell lines (CaSki, HeLa, and Ishikawa) using flow cytometry and compared with positive controls (A431 and BxPC-3) and a low-EGFR control (MCF-7). IHC was performed on cell blocks and clinical specimens of vulvar, vaginal, and cervical cancers (validation cohort, n=27; screening cohort, n=40). RESULTS: CaSki demonstrated comparable or higher EGFR binding than BxPC-3, whereas HeLa and Ishikawa showed weaker binding. IHC staining intensity correlated with flow cytometry findings. Squamous cell carcinomas consistently exhibited moderate-to-strong EGFR expression, whereas non-squamous carcinomas displayed variable expression. EGFR positivity was defined as >30% of tumor cells with at least moderate membranous staining (2+ or 3+). In the validation cohort, EGFR positivity was observed in 71.4% of the vulvar, 80.0% of the vaginal, and 87.5% of the cervical cancers. The screening cohort showed similar rates: 88.9% of vulvar, 100% of vaginal, and 75.0% of cervical cancers. CONCLUSION: We demonstrated correlation between cetuximab-binding and IHC staining intensity, establishing IHC criteria (≥2+) for patient selection. EGFR positivity (71.4%-87.5%) indicates substantial eligibility for ASP-1929 PIT. Therapeutic efficacy will be evaluated in the HICARi study. - Hokkaido phase II study of photo-immunotherapy combination with ASP-1929 for recurrent or persistent EGFR-positive vulvar, vaginal, and cervical cancers not amenable to further radiotherapy (HICARi study).
Hiroshi Asano; Hiroyuki Yamazaki; Hiroko Matsumiya; Isao Yokota; Kazufumi Okada; Ryutaro Yamamoto; Kanako C Hatanaka; Yuko Sasajima; Michiko Nagamine; Yutaka Hatanaka; Fumi Kato; Junko Takahama; Takahiro Tsuboyama; Yudai Watanabe; Naoko Okita; Hidemichi Watari
Journal of gynecologic oncology, 18 May 2026, [International Magazine]
English, Scientific journal, BACKGROUND: Photoimmunotherapy using ASP-1929 (ASP1929-PIT) is a novel approach targeting epidermal growth factor receptor (EGFR)-expressing tumors. ASP-1929, an anti-EGFR monoclonal antibody conjugated to IRDye 700DX (IR700), binds to EGFR in tumor cells. Upon exposure to 690-nm red laser light, IR700 is activated, disrupting the cellular membrane. Approved in Japan for head and neck cancer, this therapy is the first of its kind globally. Given its mechanism, ASP-1929 may also treat other EGFR-positive malignancies accessible to red light. Thus, we are conducting a phase II clinical trial of ASP1929-PIT for localized recurrent and persistent vulvar, vaginal, and cervical cancers refractory to radiotherapy (RT). These severely impact quality of life, highlighting an unmet need. METHODS: This single-arm, open-label, phase II investigator-initiated trial evaluated the efficacy and safety of ASP1929-PIT for recurrent or persistent vulvar, vaginal, or cervical cancer post-RT (jRCT2011240034). Participants had EGFR expression confirmed by immunohistochemistry, prior RT (including chemoradiotherapy) for the primary lesion, and at least one measurable vulvar, vaginal, or cervical lesion. Patients with uncontrolled distant disease or suspected mucosal invasion of the rectum or lower urinary tract were excluded. ASP-1929 (640 mg/m²) was administered via a 2-hour intravenous infusion, followed 20-28 hours later by 690-nm laser illumination. Day 1 was designated for ASP-1929 administration, with efficacy assessed between days 29 and 56. Patients could receive up to three additional treatments if a complete response was not achieved. The primary outcome was tumor shrinkage in laser-treated lesions. Sixteen patients were enrolled, with the first 4 forming a safety cohort. TRIAL REGISTRATION: Japan Registry of Clinical Trials Identifier: jRCT2011240034. - The prognosis of endometrial cancers stratified with conventional risk factors and modified molecular classification
Hiroyuki Yamazaki; Hiroshi Asano; Kanako C. Hatanaka; Ryosuke Matsuoka; Yosuke Konno; Yoshihiro Matsuno; Yutaka Hatanaka; Hidemichi Watari
Cancer Science, Sep. 2022
Scientific journal - Comparison between Urine and Cervical High-Risk HPV Tests for Japanese Women with ASC-US
Hiroyuki Yamazaki; Tsuneyuki Wada; Hiroshi Asano; Hiromasa Fujita; Kazuhira Okamoto; Hidemichi Watari
Diagnostics, 14 Oct. 2021
Scientific journal - The difficulty to diagnose cervical cancer developing in the perinatal period with the first‐trimester cytology: A retrospective study
Hiroyuki Yamazaki; Takashi Mitamura; Kei Ihira; Daisuke Endo; Manami Sakurai; Yosuke Konno; Hidemichi Watari
Journal of Obstetrics and Gynaecology Research, Wiley, 09 Jun. 2021
English, Scientific journal - Imaging-based definition of lower uterine segment carcinoma to improve the detection sensitivity of probable Lynch syndrome.
Hiroyuki Yamazaki
Japanese journal of clinical oncology, 01 Mar. 2020
Scientific journal, OBJECTIVE:The aim of this study was to investigate a magnetic resonance imaging-based definition of lower uterine segment carcinoma. METHODS:We retrospectively reviewed 587 consecutive patients with endometrial cancer who underwent hysterectomy. Lower uterine segment carcinoma was determined through pathological examination and magnetic resonance imaging assessment. For imaging assessment, the location of the inner lining of the uterus was classified into four equal parts on a sagittal section image. A tumor was defined as lower uterine segment carcinoma when its thickest part was located in the second or the third part from the uterine fundus. Lower uterine segment carcinoma was further divided into lower uterine segment in a narrow sense, upon which diagnosis was exclusively based on pathological findings, and lower uterine segment in a broad sense that were the remaining lower uterine segment carcinomas except lower uterine segment carcinomas in a narrow sense. The relationship between lower uterine segment carcinoma and probable Lynch syndrome was investigated. Patients with loss of MSH2, MSH6, and PMS2 expression or those with tumors with loss of MLH1 and absence of MLH1 promoter methylation were diagnosed as probable Lynch syndrome. RESULTS:Lower uterine segment carcinoma was identified in 59 (10.2%) patients. Twenty-eight (47.5%) patients were categorized as lower uterine segment in a narrow sense and 31 (52.5%) as lower uterine segment in a broad sense. Among them, probable Lynch syndrome was identified in 12 (20.3%) cases. There was no difference in clinical profiles, including the prevalence of probable Lynch syndrome between the two categories. CONCLUSIONS:A magnetic resonance imaging-based expanded definition of lower uterine segment carcinoma is likely to secure characteristics equivalent to a conventional pathology-based definition of lower uterine segment carcinoma. The novel definition of lower uterine segment carcinoma might improve the detection of probable Lynch syndrome. - Therapeutic significance of full lymphadenectomy in early-stage ovarian clear cell carcinoma
Hiroyuki Yamazaki; Yukiharu Todo; Chisa Shimada; Sho Takeshita; Shinichiro Minobe; Kazuhira Okamoto; Katsushige Yamashiro; Hidenori Kato
Journal of Gynecologic Oncology, 29, 2, Asian Society of Gynecologic Oncology$\mathsemicolon$ Korean Society of Gynecologic Oncology and Colposcopy ({KAMJE}), 2018
Scientific journal - A prediction model of survival for patients with bone metastasis from uterine cervical cancer
Hiroko Matsumiya; Yukiharu Todo; Kazuhira Okamoto; Sho Takeshita; Hiroyuki Yamazaki; Katsushige Yamashiro; Hidenori Kato
Journal of Gynecologic Oncology, 27, 6, Asian Society of Gynecologic Oncology$\mathsemicolon$ Korean Society of Gynecologic Oncology and Colposcopy ({KAMJE}), 2016
Scientific journal - Relationship between removal of circumflex iliac nodes distal to the external iliac nodes and postoperative lower-extremity lymphedema in uterine cervical cancer.
Hiroyuki Yamazaki
Gynecologic oncology, 10 Sep. 2015
Scientific journal,Objective
This study aimed to determine if there is a causal relationship between removal of the circumflex iliac nodes distal to the external iliac nodes (CINDEIN) and postoperative lower-extremity lymphedema (POLEL) after systematic lymphadenectomy in patients with cervical cancer.Methods
A retrospective chart review was performed for all living cervical cancer patients who underwent lymphadenectomy and were managed at Hokkaido Cancer Center between 1993 and 2013. The type of lymphadenectomy gradually shifted from lymphadenectomy with removal of CINDEIN to without CINDEIN dissection during this period. The study period was divided into two phases: from 1993-2007 (first phase) and from 2008-2013 (second phase). We identified patients with POLEL. Logistic regression analysis was used to select the risk factors for POLEL.Results
Implementation of CINDEIN-dissection lymphadenectomy (94.0% vs. 20.6%, p<0.0001) and adjuvant radiotherapy (26.1% vs. 4.5%, p<0.0001) was significantly higher in the first phase than in the second phase. Of 398 patients evaluated, POLEL was noted in medical records of 80 (20.1%) patients with a median follow-up period of 78.0months. The occurrence rate of POLEL was significantly higher in the first phase than in the second phase (32.2% vs. 8.0%, p<0.0001), despite no change in the number of dissected lymph nodes between the two phases. Multivariate analysis showed that adjuvant radiation therapy (odds ratio=2.6, 95% confidence interval=1.4-4.8) and removal of CINDEIN (odds ratio=4.6, 95% confidence interval=2.4-9.0) were independent risk factors for POLEL.Conclusion
Elimination of CINDEIN dissection is helpful for reducing the incidence of POLEL. - Pretreatment risk factors for parametrial involvement in FIGO stage IB1 cervical cancer.
Hiroyuki Yamazaki
Journal of gynecologic oncology, 14 Jul. 2015
Scientific journal,Objective
All patients with stage IB1 cervical cancer do not need to undergo parametrectomy. Some low-risk criteria for parametrial involvement (PI) have been proposed based on pathological findings. The aim of this study was to determine pretreatment risk factors for PI in stage IB1 cervical cancer.Methods
We retrospectively reviewed 115 patients with stage IB1 cervical cancer who underwent radical hysterectomy or radical trachelectomy. Magnetic resonance imaging (MRI) was performed and serum concentrations of squamous cell carcinoma antigen (SCC-Ag) and cancer antigen 125 (CA-125) were determined in all patients before initial treatment. The following pretreatment factors were investigated: histological variant, maximum tumor diameter, tumor volume (volume index), pelvic lymph node enlargement, and serum tumor markers. Logistic regression analysis was used to select the independent risk factors for PI.Results
Eighteen of the 115 patients (15.7%) were pathologically diagnosed with PI. Multivariate analysis confirmed the following independent risk factors for PI: MRI-based tumor diameter ≥ 25 mm (odds ratio [OR], 9.9; 95% confidence interval [CI], 2.1 to 48.1), MRI-based volume index ≥ 5,000 mm³ (OR, 13.3; 95% CI, 1.4 to 125.0), and positive serum tumor markers SCC-Ag ≥ 1.5 ng/mL or CA-125 ≥ 35 U/mL (OR, 5.7; 95% CI, 1.3 to 25.1). Of 53 patients with no risk factors for PI, none had PI.Conclusion
Less radical surgery may become one of the treatment options for stage IB1 cervical cancer patients with MRI-based tumor diameter <25 mm, MRI-based volume index <5,000 mm³, and negativity for SCC-Ag and CA-125.
- A case of parasitic leiomyoma following total laparoscopic hysterectomy without use of power morcellation: A case report
Ishizuka Yasunari; Kudo Masataka; Ohara Yasuhiro; Yamazaki Hiroyuki; Ihira Kei; Uda Tomohiro; Nakatani Makiko; Kato Tatsuya; Watari Hidemichi; Sakuragi Noriaki, JAPANESE JOURNAL OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY, 33, 1, 131, 137, Apr. 2017Background: The number of gynecological laparoscopic procedures is increasing. Power morcellation has been widely employed to break up large uterine fibroids and remove fragments from the abdominal cavity. In recent years, several studies have reported parasitic leiomyoma (PM), resulting from the spread and growth of fibroid tissues in the abdominal cavity after the use of power morcellation for laparoscopic hysterectomy or myomectomy.
Case: A 46-year-old para 1 woman had undergone total laparoscopic hysterectomy for a large uterine leiomyoma at the age of 41 without use of power morcellation. Fiftynine months later, she was found to have intrapelvic tumors. Following surgical resection they were diagnosed as iatrogenic PMs.
Conclusions: It is possible that iatrogenic PM can occur even if power morcellation is not used. Surgeons must be careful to remove as many small fragments of fibroids as possible. We should be aware of the risk for iatrogenic PMs in all surgical procedures for uterine fibroids. To our knowledge, this is the first report of a case of iatrogenic PM after total laparoscopic hysterectomy without the use of power morcellation.
, JAPAN SOCIETY OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY AND MINIMALLY INVASIVE THERAPY, Japanese - 子宮頸癌に対する広汎子宮全摘術後の補助化学療法の有用性についての後方視的検討
嶋田 知紗; 加藤 達矢; 朝野 拓史; 山崎 博之; 井平 圭; 遠藤 大介; 福本 俊; 宇田 智浩; 中谷 真紀子; 古田 祐; 三田村 卓; 金野 陽輔; 武田 真人; 小林 範子; 工藤 正尊; 渡利 英道; 櫻木 範明, 日本婦人科腫瘍学会雑誌, 34, 3, 434, 434, Jun. 2016
(公社)日本婦人科腫瘍学会, Japanese
- 検尿カップによる自己採尿検体を用いた子宮頸がん検診の実施可能性についての検討
第75回日本産科婦人科学会学術講演会, 13 May 2023, Poster presentation
12 May 2023 - 14 May 2023
- Development of new gene panel system for molecular classification of endometrial cancer and genetic analysis to search for therapeutic targets
Grants-in-Aid for Scientific Research
01 Apr. 2024 - 31 Mar. 2027
渡利 英道; 畑中 佳奈子; 金野 陽輔; 畑中 豊; 朝野 拓史; 山崎 博之
Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), Hokkaido University, 24K02581
